Autoimmune myasthenia gravis

G. Lopate, A. Pestronk

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

The evident defect in this disease is postsynaptic dysfunction due to antiacetylcholine receptor antibodies. The postsynaptic membrane is simplified, the number of acetylcholine receptors is reduced, and neuromuscular transmission is impaired. Antiacetylcholinesterase drugs still play a role in management. Newer options include prednisone, azathioprine, and cyclosporine.

Original languageEnglish
Pages (from-to)109-112+115+117+121-122+127-128+131
JournalHospital Practice
Volume28
Issue number1
DOIs
StatePublished - Jan 1 1993

Fingerprint

Dive into the research topics of 'Autoimmune myasthenia gravis'. Together they form a unique fingerprint.

Cite this